The Food and Drug Administration is looking at taking a more active role in switching prescription medications to over the counter. Under the current system, manufacturers of the drugs play the most active role in determining which drugs change to OTC.
The Food and Drug Administration is looking at taking a more active role in switching prescription medications to over the counter. Under the current system, manufacturers of the drugs play the most active role in determining which drugs change to OTC.
At an FDA hearing on the subject, Pharmaceutical Research and Manufacturers of America General Council and Senior Vice President Russel A. Bantham testified that the current system is the best way to ensure that forced OTC changes do not put patients at risk or force manufacturers to assume unwanted liability risks.
"⦠[M]anufacturers have the most comprehensive and detailed knowledge of their drugs, including information bearing on whether a drug is a suitable switch candidate." Bantham told an FDA panel. "Taking all this into account, manufacturers are in the best position to decide when to begin the switch process and thereby avoid premature switches that could put some members of the public at risk."
Those in favor of the Food and Drug Administration taking more control of the process, however, claim that the pharmaceutical industry has a financial stake in delaying moving some drugs to over the counter, even though many of these drugs could be used safely without the supervision of a physician.
"Ideally, the agency would consider input from many sources [when considering an OTC switch] - including health professionals, consumers, medical researchers and insurers," said Health Insurance Association of America President Charles Kahn in his testimony before the FDA. "It is important that a drug be switched only when it's safe to do so, but when it's safe, making medications over the counter provides a direct cost savings to the consumer and may also save lives." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.